EBMT 2022 | Improving the management of GvHD

Ernst Holler • 21 Mar 2022

EBMT 2022

General Cyclophosphamide

Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany outlines some strategies to improve the management of graft-versus-host disease (GvHD). This includes earlier risk-adapted treatments, because current immunosuppressive treatments cause significant toxicity. Additionally, Prof. Holler highlights the benefits of using more personalized treatments and better prophylaxis strategies that do not impact the graft-versus-leukemia (GvL) effect. Prof. Holler also talks on the benefits of post-transplant cyclophosphamide (PTCy), which has significantly reduced the incidence of acute GvHD. Lastly, Prof. Holler mentions that due to the heterogeneous nature of chronic GvHD, it may be beneficial to develop different treatments for the different disease subtypes. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.